23andMe will no longer provide “outside app developers” access to the company’s raw genetic data, CNBC reported.
As millions of people pay for home tests to check on ancestry or health risks, genetic data is becoming an increasingly valuable resource for drugmakers, triggering a race to create a DNA marketplace.
Regeneron Pharmaceuticals Inc. announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project the company believes could help accelerate new drug discovery and improve approval success rates.
23andMe, working in collaboration with the Milken Institute and Lundbeck, announced that they have commenced enrollment for a first-of-its kind genetic study designed to gain understanding of the underlying biology of major depressive and bipolar disorders.
Dutch healthcare technology company Philips said Thursday it had reached deals with New York’s Memorial Sloan Kettering Cancer Center (MSK) and Utah-based Intermountain Healthcare for them to use its genomics platform for cancer research and treatment.